ZIOPHARM Oncology, Inc. Presents Preclinical Data At American Association for Cancer Research Annual Meeting Supporting Controlled DNA-Based IL-12 Therapy For Brain Cancer
Published: Apr 09, 2014
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine model. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled, local expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response.
Help employers find you! Check out all the jobs and post your resume.